Adcetris (brentuximab vedotin)

P2/3, N=374, Not yet recruiting, National Cancer Institute (NCI)

P2, N=62, Active, not recruiting, City of Hope Medical Center | Trial completion date: Mar 2026 --> Feb 2027

P2, N=150, Recruiting, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Active, not recruiting --> Recruiting

There was no significant difference between the cyclophosphamide, doxorubicin, vincristine, prednisone and etoposide regimen and the cyclophosphamide, vincristine, doxorubicin and prednisone regimen, whereas combinations with chidamide showed a trend toward an improved PFS. Within the cohort, 2 patients with relapsed and refractory CD30-positive PTCL-NOS received salvage chemotherapy with brentuximab vedotin (BV), a monoclonal antibody, and achieved complete metabolic remission, followed by sequential allogeneic haematopoietic stem-cell transplantation, resulting in long-term sustained remission. In conclusion, patients diagnosed with PTCL-NOS generally have a poor prognosis. Nevertheless, the use of innovative targeted therapies, such as chidamide and BV, shows potential to improve treatment outcomes in these patients.

Furthermore, the addition of eliglustat also enhanced the tumor-killing activity of brentuximab vedotin (BV), a CD30-directed antibody-drug conjugate, both in vitro and in vivo. This glycoimmunotherapy paradigm represents a clinically actionable approach to overcome glycan-mediated immune evasion and enhance therapeutic efficacy in CD30-positive lymphomas.

P2, N=23, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Trial completion date: Nov 2027 --> Oct 2029 | Trial primary completion date: Nov 2027 --> Oct 2029

Brentuximab vedotin-based regimens have reshaped frontline therapy for CD30-positive disease, while ongoing studies are exploring the role of novel therapies including epigenetic modulators, phosphatidylinositol 3-kinase (PI3K) and JAK inhibitors, and immune-based therapies across the PTCL spectrum. Future progress will depend on biomarker-driven clinical trials, refined patient selection, and the incorporation of genomic and immune signatures to personalize therapy.

P=N/A, N=33, Huashan Hospital, Fudan University; Huashan Hospital, Fudan University

P3, N=239, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial primary completion date: Dec 2026 --> Jan 2026

Recent years have seen a shift away from chemotherapy with the approval of targeted therapies like mogamulizumab, brentuximab vedotin, and denileukin diftitox-cxdl. Though these novel agents have improved outcomes for patients with advanced-stage CTCL, most patients will continue to experience relapses. Emerging agents, including lacutamab, resminostat, and immune checkpoint inhibitors and biomarkers including CD5, CD70, and CD47/Sirpα represent the next frontier in maintaining durable remissions and improving quality of life (QoL) for these patients.

After a dose of ifosfamide/etoposide elsewhere, therapy was revised to ifosfamide, carboplatin, and etoposide plus brentuximab vedotin, with marked improvement by 2 cycles and cutaneous resolution by 5; she died of cardiopulmonary failure before the sixth cycle. This case underscores generous sampling, focused immunohistochemistry, and staging; negative ALK/EMA does not exclude systemic disease, and CD30-directed therapy can yield rapid cutaneous responses.

To mitigate pulmonary and myelotoxicity risks, he received a modified regimen of brentuximab vedotin (BV) combined with adriamycin, vinblastine, and dacarbazine (BV-AVD), with full omission of bleomycin. It underscores the critical need for individualized therapy in patients with DC and supports careful consideration of radiation omission to reduce secondary malignancy risk. These findings provide a potential therapeutic framework for managing Hodgkin lymphoma in patients with DC.